Chardan Capital Downgrades Eyepoint Pharmaceuticals (NASDAQ:EYPT) to Neutral

Eyepoint Pharmaceuticals (NASDAQ:EYPT) was downgraded by research analysts at Chardan Capital from a “buy” rating to a “neutral” rating in a research report issued to clients and investors on Tuesday. They presently have a $5.00 price objective on the stock. Chardan Capital’s target price points to a potential upside of 2.67% from the stock’s current price.

A number of other research analysts have also recently weighed in on the stock. Jefferies Financial Group dropped their price objective on shares of Eyepoint Pharmaceuticals to $8.00 and set a “buy” rating for the company in a report on Monday. Stifel Nicolaus started coverage on shares of Eyepoint Pharmaceuticals in a report on Thursday, July 16th. They set a “buy” rating and a $40.00 target price on the stock. Cantor Fitzgerald cut shares of Eyepoint Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research report on Monday. JPMorgan Chase & Co. restated a “neutral” rating on shares of Eyepoint Pharmaceuticals in a research note on Monday. Finally, Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $5.00 price objective on shares of Eyepoint Pharmaceuticals in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $30.11.

Eyepoint Pharmaceuticals Price Performance

Shares of Eyepoint Pharmaceuticals stock opened at $4.87 on Tuesday. The stock has a market capitalization of $419.84 million, a price-to-earnings ratio of -1.30 and a beta of 1.76. The business has a 50-day moving average of $13.10 and a 200 day moving average of $13.62. Eyepoint Pharmaceuticals has a 12 month low of $3.95 and a 12 month high of $19.11.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.08). The business had revenue of $0.51 million for the quarter, compared to analysts’ expectations of $0.45 million. Eyepoint Pharmaceuticals had a negative return on equity of 135.81% and a negative net margin of 10,994.73%. Equities research analysts anticipate that Eyepoint Pharmaceuticals will post -3.6 earnings per share for the current year.

Hedge Funds Weigh In On Eyepoint Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. California State Teachers Retirement System raised its holdings in Eyepoint Pharmaceuticals by 20.6% in the fourth quarter. California State Teachers Retirement System now owns 4,654 shares of the company’s stock valued at $85,000 after acquiring an additional 794 shares in the last quarter. RWC Asset Management LLP lifted its stake in Eyepoint Pharmaceuticals by 6.4% in the fourth quarter. RWC Asset Management LLP now owns 17,235 shares of the company’s stock worth $315,000 after acquiring an additional 1,040 shares during the last quarter. MCF Advisors LLC grew its holdings in Eyepoint Pharmaceuticals by 8.3% during the 4th quarter. MCF Advisors LLC now owns 14,921 shares of the company’s stock worth $273,000 after acquiring an additional 1,149 shares in the last quarter. Raymond James Financial Inc. grew its holdings in Eyepoint Pharmaceuticals by 11.0% during the 2nd quarter. Raymond James Financial Inc. now owns 11,900 shares of the company’s stock worth $112,000 after acquiring an additional 1,177 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in shares of Eyepoint Pharmaceuticals by 51.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,023 shares of the company’s stock valued at $74,000 after purchasing an additional 1,358 shares during the last quarter. 99.41% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Eyepoint Pharmaceuticals

Here are the key news stories impacting Eyepoint Pharmaceuticals this week:

• Positive Sentiment: EyePoint said DURAVYU was non-inferior to on-label aflibercept in an ad hoc analysis that excluded an asymmetric cohort of nine patients whose vision loss was considered unrelated to wet AMD. The trial also showed a 42% reduction in treatment burden, strong anatomic control through Week 56, supplement-free treatment rates and a favorable redosing safety profile. EyePoint Announces Topline Data from LUGANO
• Positive Sentiment: Jefferies lowered its price target to $8 but maintained a “buy” rating, while Chardan reaffirmed its “buy” rating and $65 target. These bullish views indicate some analysts believe the LUGANO result may be addressable and that DURAVYU’s longer-duration treatment profile retains value.
• Neutral Sentiment: Trading in EYPT was temporarily halted for pending news before the trial results were released, reflecting the material importance of the announcement. JPMorgan reaffirmed its “neutral” rating.
• Negative Sentiment: The full trial dataset did not meet the primary endpoint because the unusual vision-loss cohort affected the result. Investors now face greater regulatory and clinical uncertainty, particularly while awaiting the second pivotal Phase 3 trial. EyePoint’s eye drug misses main goal in late-stage trial
• Negative Sentiment: Cantor Fitzgerald downgraded EyePoint from “overweight” to “neutral.” The setback prompted speculation that competing ophthalmology companies, including Ocular Therapeutix and Forma Therapeutics, may now appear more attractive, further pressuring EYPT’s valuation.

Eyepoint Pharmaceuticals Company Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.